2a - 60 day FRN

Federal Register / Vol. 77, No. 199 / Monday, October 15, 2012 / Notices
to the purpose or are inadequate, new
improved objectives and/or new
measures should be developed. Whether
or not an objective has met its target in
a previous Healthy People iteration
should not be the sole basis for retaining
or deleting an objective.
7. The objectives should be supported
by the best available scientific evidence.
The objective selection and review
processes should be flexible enough to
allow revisions to objectives in order to
reflect major updates or new knowledge.
8. Objectives should address
population disparities. These include
populations categorized by race/
ethnicity, socioeconomic status, gender,
disability status, sexual orientation, and
geographic location. For particular
health issues, additional special
populations should be addressed, based
on an examination of the available
evidence on vulnerability, health status,
and disparate care.
9. Healthy People 2020, like past
versions, will be heavily data driven.
Valid, reliable, nationally representative
data and data systems should be used
for Healthy People 2020 objectives. Each
objective will have (1) a data source, or
potential data source, identified, (2)
baseline data and (3) assurance of at
least one additional data point
throughout the decade.
Dated: October 1, 2012.
Don Wright,
Deputy Assistant Secretary for Health, Office
of Disease Prevention and Health Promotion.
[FR Doc. 2012–25259 Filed 10–12–12; 8:45 am]
BILLING CODE 4150–32–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–13–0612]

erowe on DSK2VPTVN1PROD with

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 and

VerDate Mar<15>2010

15:21 Oct 12, 2012

Jkt 229001

send comments to Ronald Otten, CDC
Reports Clearance Officer, 1600 Clifton
Road, MS–D74, Atlanta, GA 30333 or
send an email to [email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Well-Integrated Screening and
Evaluation for Women Across the
Nation (WISEWOMAN) Reporting
System (OMB #0920–0612, exp. 3/31/
2013)—Extension—National Center for
Chronic Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Cardiovascular disease (CVD), which
includes heart disease, myocardial
infarction, and stroke, is the leading
cause of death for women in the United
States, and is largely preventable. The
WISEWOMAN program (Well-Integrated
Screening and Evaluation for Women
Across the Nation), administered by the
Centers for Disease Control and
Prevention (CDC), was established to
examine ways to improve the delivery
of services for women who have limited
access to health care and elevated risk
factors for CVD. The program focuses on
reducing CVD risk factors and provides
screening services for select risk factors
such as elevated blood cholesterol,
hypertension and abnormal blood
glucose levels. The program also
provides lifestyle interventions and
medical referrals. On an annual basis,
21 grantees funded through the
WISEWOMAN program have provided
services to approximately 30,000
women who are already participating in
the National Breast and Cervical Cancer
Early Detection Program (NBCCEDP),
also administered by CDC.
CDC currently collects information
from WISEWOMAN grantees to support
continuous program monitoring and

PO 00000

Frm 00026

Fmt 4703

Sfmt 4703

62515

improvement activities. CDC seeks to
extend OMB approval for one additional
year. There are no changes to the
number of respondents, the data items
reported to CDC, the estimated burden
per response, or the total estimated
annualized burden. All information will
continue to be collected twice per year.
Information reported to CDC includes
baseline and follow-up data (12 months
post enrollment) for all women served
through the WISEWOMAN program.
These data, called the minimum data
elements (MDE), include data elements
that describe risk factors for the women
served in each program and data
elements that describe the number and
type of intervention sessions attended.
Funded grantees compile the data from
their existing databases and report the
MDE to CDC on April 15th and October
15th of each year.
The MDE data provide an assessment
of how effective the WISEWOMAN
program is at reducing the burden of
cardiovascular disease risk factors
among women who utilize program
services. The information collected from
grantees is also used to assess the costeffectiveness and impact of the program.
Because certain demographic
information has already been collected
as part of NBCCEDP, the additional
burden of WISEWOMAN program
reporting is modest.
The overall program evaluation is
designed to demonstrate how
WISEWOMAN can obtain more
complete health data on vulnerable
populations, promote public education
about disease incidence and risk-factors,
improve the availability of screening
and diagnostic services for under-served
women, ensure the quality of services
provided to under-served women, and
develop strategies for improved
interventions. The information reported
to CDC also includes programmatic
information related to grantee
management, public education and
outreach, professional education,
service delivery, cost, and progress
toward meeting stated programmatic
objectives.
All MDE information will be
submitted to CDC electronically. The
estimated burden per response for
Screening and Assessment MDE is 16
hours. The estimated burden per
response for Lifestyle Intervention MDE
is 8 hours. Progress reports will be
submitted in hardcopy format. The
estimated burden per response for each
progress report is 16 hours.

E:\FR\FM\15OCN1.SGM

15OCN1

62516

Federal Register / Vol. 77, No. 199 / Monday, October 15, 2012 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden
per
response
(in hr)

Number of
responses
per
respondent

Total
burden
(in hr)

Type of respondent

Form name

WISEWOMAN Grantees ...................

Screening and Assessment MDE ....
Lifestyle Intervention MDE ...............
Progress Report ...............................

21
21
21

2
2
2

16
8
16

672
336
672

Total ...........................................

...........................................................

........................

........................

........................

1,680

Dated: October 9, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI),
Office of the Associate Director for Science
(OADS), Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2012–25251 Filed 10–12–12; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

[60Day–13–0923]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 or send
comments to Ronald Otten, CDC Reports
Clearance Officer, 1600 Clifton Road,
MS D–74, Atlanta, GA 30333 or send an
email to [email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.

VerDate Mar<15>2010

15:21 Oct 12, 2012

Jkt 229001

Proposed Project
Evaluation of the National Tobacco
Prevention and Control Public
Education Campaign (OMB No. 0920–
0923, exp. 2/28/2013)—Revision—
National Center for Chronic Disease
Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description

Centers for Disease Control and
Prevention

erowe on DSK2VPTVN1PROD with

Number of
respondents

In 2012, CDC obtained OMB approval
to collect information needed to
evaluate CDC’s National Tobacco
Prevention and Control Public
Education Campaign (The Campaign)
(OMB No. 0920–0923, exp. 2/28/2013).
The evaluation plan was based on two
waves of data collection conducted in
2012: An initial baseline survey before
the launch of The Campaign (wave 1),
and a longitudinal follow-up survey of
those participants approximately three
months after the conclusion of The
Campaign (wave 2). The pre/post
assessment design allowed CDC to
examine the association between
smokers’ and nonsmokers’ exposure to
The Campaign and changes in outcome
variables of interest.
CDC recently announced plans to
launch a second phase of The Campaign
(Phase 2) using the same campaign
name (‘‘Tips from Former Smokers’’),
similar advertisement styles, similar
message themes and strategies, and in
some cases the same ad cast members.
In order to apply a similar evaluation
strategy to Phase 2 of The Campaign,
CDC is requesting changes to the
previously approved information
collection plan. These changes include
one additional survey in 2013 (wave 3),
and changes to the previously approved
follow-up questionnaires.
The evaluation plan for Phase 2 will
utilize a similar study design (pre/post
assessment) and the same sample
sources that were utilized in the first
phase of campaign evaluation. In 2013,
CDC plans to administer 13,750
additional follow-up questionnaires to
smokers sourced through the
Knowledge Networks (KN) online panel

PO 00000

Frm 00027

Fmt 4703

Sfmt 4703

and the Survey Sampling International
(SSI) online panel, and 3,286 additional
questionnaires to nonsmokers drawn
from the KN Panel. Because respondents
in 2013 will be drawn from the same
sources utilized in 2012, CDC will be
able to conduct longer-term longitudinal
analysis of respondents who participate
in both the first wave (2012) and third
wave (2013) of information collection.
CDC will assess relevant outcome
measures prior to initiation of Phase 1
of The Campaign, and after completion
of the combined Phase 1 and Phase 2
campaigns.
The analysis plan for Phase 2 of The
Campaign will allow CDC to estimate
smokers’ and nonsmokers’ exposure to
Phase 2 campaign messages,
characterize respondents’ reactions to
Phase 2 campaign messages, describe
changes in knowledge, attitudes, and
beliefs related to smoking and
secondhand smoke, and quantify the
number of quit attempts made during
the Phase 2 campaign. The revised
follow-up questionnaires for 2013 will
be similar to the questionnaires
administered in 2012, however, changes
will be made to measure new outcomes
targeted by the Phase 2 campaign, such
as knowledge of the association between
smoking and diabetes, and knowledge of
the relationship between secondhand
smoke exposure and heart attacks.
The Phase 2 Campaign is expected to
launch in early winter/spring 2013 and
will air for approximately three months.
To ensure accurate measurement of
campaign awareness after all media
have been delivered, wave 3 data
collection will occur approximately
three months after the launch of Phase
2 messages. Information will be
collected about smokers’ and nonsmokers’ awareness of and exposure to
campaign advertisements; knowledge,
attitudes, and beliefs related to smoking
and secondhand smoke; and behaviors
related to smoking cessation (among the
smokers in the sample) and behaviors
related to non-smokers’ encouragement
of smokers to quit smoking.
Respondents will undergo a brief
screening process to ensure that they

E:\FR\FM\15OCN1.SGM

15OCN1